Maybe some here remember what has happened to Biogen (BIIB) when they developed Tysbari (Natalizumab) for multiple sclerosis.....It caused a very serious brain side effect called PML. Nevertheless, the FDA did not remove it from the market and it is still in the clinic because the benefits outweighed the risks. BIIB stock also took it on the chin when it was announced. I believe that the same situation is also pertinent to Ariad's drug. It is a blow to Ariad..no doubt, but these things do happen. All in all, the drug is aimed at cancer patients who have extremely few tratment choices, and on the other hand it has significant cancer responses. So...to those who are long, sit back, relax and watch what happens to Ariad's drug. I bet you dollars to doughnuts it wouldnot be taken off the market and the company will use 30 or even 15 mgs treatment instead of the 45 mg used now. Also, it has a significant amount of cash and a second drug candidate in clinical development for lung cancer. The problem is that like with BIIB, it will probably take two years to sort this mess out.....GDoc.